| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 1,824.2 Million |
| Market Size in 2026 | USD 1,939.1 Million |
| Market Size by 2032 | USD 2,942.8 Million |
| Projected CAGR | 7.1% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Fragmented |
Explore the market potential with our data-driven report
The analytical standards market size was USD 1,824.2 million for 2025, and it will grow by 7.1% during 2026–2032, to reach USD 2,942.8 million by 2032.
This growth is driven by tightening method-validation obligations across pharmaceutical quality control, environmental contaminant surveillance, and food authenticity testing, positioning certified reference materials as the traceability backbone of regulated laboratory workflows. Analytical standards are high-purity reference substances or materials used in analytical testing and quality assurance. Electrophoresis, chromatography, titration, and spectroscopy are a few of the processes wherein such compounds are used for quantitative and trace analysis.
The global market is expanding due to the growing application of the associated products in pharmaceutical, biotechnology, food safety and quality assurance, environmental analysis, forensics, and many other applications. Additionally, the rising concern for food safety and quality and product stability, degradation, impurity, and shelf-life analysis, driven by the stringent government rules in this regard, is propelling the usage of analytical standards.
Analytical standards are increasingly becoming integrated into digital laboratory workflows rather than being sourced solely as standalone catalogue purchases. As compendial content becomes more accessible in machine-readable formats and is integrated with laboratory information management systems, electronic laboratory notebooks, and other digital platforms, analytical standards can become more closely linked to analytical methods, supporting greater efficiency in method execution and procurement workflows.
The U.S. Pharmacopeia (USP) launched USP MethodConnect in May 2026, providing a machine-readable library of USP–NF test methods containing acceptance criteria, calculations, and general chapter instructions for integration into digital laboratory platforms, while also advancing the digitization of reference materials through the development of nearly 1,000 digital analytical reference materials (dARMs), which leverage nuclear magnetic resonance (NMR) and quantum mechanics to enable the digital delivery of chemical reference materials to customers. The increasing digitization of compendial methods and reference materials is expected to influence how laboratories identify, access, and procure analytical standards. Suppliers that provide detailed digital metadata, traceability information, and clear mapping of materials to relevant compendial methods may gain greater visibility within laboratory workflows. This trend is also supporting closer integration between analytical instruments, laboratory informatics platforms, analytical methods, and reference materials.
The continued expansion of clinical research is supporting demand for analytical standards and reference materials used in pharmaceutical development, bioanalytical testing, assay validation, impurity characterization, and quantitative analysis. As the number of clinical studies increases, pharmaceutical and biotechnology companies, contract research organizations (CROs), and testing laboratories require qualified reference materials to support analytical methods used throughout drug development and quality assessment.
The U.S. National Library of Medicine (NLM) reports that ClinicalTrials.gov surpassed 500,000 registered studies during 2024, covering studies conducted across all 50 U.S. states and 226 countries and territories. The growing volume of registered clinical research reflects the expanding scale of pharmaceutical and biotechnology development and is expected to support demand for analytical standards used in research and bioanalytical testing. The increasing use of contract research and testing organizations is further supporting demand for reference materials as analytical testing and bioanalytical activities are increasingly outsourced. The growing development of biologics, antibody-drug conjugates, and cell and gene therapies is also creating demand for specialized and application-specific reference materials, including materials required for method development, validation, characterization, and quality-control testing.
Limited availability of skilled analytical personnel can constrain laboratory capacity and the adoption of advanced testing methods in some mature markets. Increasing regulatory and quality-control requirements are creating demand for analytical testing, while laboratories must simultaneously manage the availability of qualified personnel with expertise in analytical chemistry, method development, validation, and instrument operation. This can limit the pace at which laboratories expand testing capacity and adopt additional analytical methods.
Cost structures associated with high-purity and certified analytical standards can also limit adoption, particularly among smaller laboratories. Multi-stage purification, characterization, homogeneity and stability testing, certification, and quality-management requirements can increase the cost of premium reference materials, while customized standards may involve extended production and delivery lead times. These cost and capacity pressures may constrain market expansion through 2032, particularly for laboratories operating under limited testing budgets.
Increasing regulatory restrictions on chemical substances are creating additional requirements for analytical testing across manufacturing and supply chains. Restrictions on substance classes such as per- and polyfluoroalkyl substances (PFAS) are increasing the need for laboratories and manufacturers to identify, quantify, and verify restricted substances in products, materials, and environmental matrices. This is supporting demand for analytical standards and reference materials used in regulatory compliance, method validation, and chemical characterization.
The European Chemicals Agency (ECHA) is evaluating a proposed EU-wide restriction covering more than 10,000 PFAS substances across multiple sectors and applications. ECHA's scientific committees are evaluating the proposal, with the Socio-Economic Analysis Committee expected to adopt its final opinion by the end of 2026. The proposal addresses the manufacture, placing on the market, and use of PFAS and covers a broad range of sectors. The expansion of class-based chemical restrictions is expected to increase demand for analytical standards used in product testing, environmental monitoring, material characterization, and regulatory compliance. In particular, testing requirements for complex matrices such as polymers, coatings, textiles, electronics, and other manufactured materials may create opportunities for suppliers offering specialized reference materials and standards suited to specific analytical methods and matrices.
The chromatography category holds the largest market share, of 45%, in 2025. This is attributed to the increasing pharmaceutical and biopharmaceutical R&D activities and technological advancements. Chromatography helps in detecting the constituents of a chemical mixture and separating them, monitoring dissolved contents in freshwater and marine ecosystems, studying the emission lines of distant galaxies, altering drug structures to improve effectiveness, and characterizing proteins. The advance of the category is, thus, attributed to the rising population impacted by chronic illnesses, which drives the demand for medication.
The spectroscopy category will have the highest CAGR, of approximately 7.4%, supported by the increasing adoption of spectroscopic techniques, particularly Raman spectroscopy, for material identification, characterization, process monitoring, and quality control in pharmaceutical and other industrial applications. The European Directorate for the Quality of Medicines & HealthCare (EDQM) confirms that the European Pharmacopoeia Commission adopted a revised general chapter on Raman spectroscopy, reflecting the increasing use of Raman instruments in pharmaceutical environments. The revised chapter also includes requirements related to spectral resolution and updates reference substances used for wavenumber-scale verification.
The techniques analyzed in this report are:
The pharmaceutical & life sciences category holds the largest market share, of 35%, in 2025, owing to the rising number of clinical research and trial activities, which increase the use of analytical standards for studying the chemical and physical stability of drugs. The segment's leading position is further supported by extensive analytical testing requirements associated with pharmaceutical development and manufacturing, including assay determination, impurity profiling, dissolution testing, stability assessment, and batch-release testing. The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that the pharmaceutical industry invested approximately EURO 55 billion in research and development in Europe during 2024, supporting continued drug development and analytical testing activities and, consequently, demand for analytical standards and reference materials.
The environmental sciences category will have the highest CAGR, driven by increasing regulatory focus on contaminants and the expansion of environmental monitoring requirements, which are increasing the need for analytical standards used to identify and quantify pollutants in water, soil, and other environmental matrices. The European Environment Agency (EEA) reports that only 30% of Europe’s surface waters achieve good chemical status, increasing to 77% when ubiquitous, persistent, bioaccumulative, and toxic substances are excluded. The agency also highlights the increasing detection of emerging contaminants, including microplastics, pharmaceuticals, and personal care products, in aquatic systems. The expansion of environmental monitoring and regulatory requirements for emerging contaminants is expected to increase demand for analytical standards and reference materials used in pollutant identification, quantification, method validation, and regulatory compliance.
The applications analyzed in this report are:
The bioanalytical testing category holds the largest market share in 2025, supported by the extensive use of bioanalytical testing throughout pharmaceutical research and development, including pharmacokinetic, bioequivalence, toxicokinetic, and drug-metabolism studies. These studies require quantitative determination of drugs, metabolites, and other analytes across multiple samples, supporting demand for analytical standards used in calibration, quality-control, method development, and validation. The U.S. Food and Drug Administration (FDA) bioanalytical method validation guidance applies to both chromatographic and ligand-binding assays and includes expectations related to the characterization and use of reference standards during analytical method development.
The stability testing category will have the highest CAGR, of approximately 7.6%, supported by evolving stability-testing requirements and the expanding development of complex pharmaceutical products and advanced therapies. The International Council for Harmonisation (ICH) advanced its consolidated draft Q1 guideline on stability testing of drug substances and drug products to Step 2b on April 11, 2025. The proposed guideline consolidates existing stability guidance and expands its scope to additional product categories, including oligonucleotides, proteins, vaccines, cell-based therapies, and gene therapies.
The methodologies analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 40%, in 2025, driven by strong pharmaceutical R&D, biotechnology growth, stringent quality standards, and advanced analytical infrastructure. The presence of major manufacturers has led to the high demand for analytical standards and reference materials from the pharmaceutical and chemical industries in the region.
Further, there has been high penetration of analytical technologies and methods among laboratories for environmental pollution monitoring, drug testing, forensics, food testing, and other purposes. Moreover, the high per capita income and advanced laboratory infrastructure and stringent quality-control requirements in the U.S. and Canada are supporting market growth. According to U.S. Food and Drug Administration (FDA) data, the Center for Drug Evaluation and Research (CDER) approved 46 novel drugs in 2025, including new molecular entities and new therapeutic biological products. The continued development and regulatory approval of novel pharmaceutical products support demand for analytical testing, method validation, and reference materials used in pharmaceutical quality assessment.
The U.S. is the largest country market within North America, supported by its advanced national measurement infrastructure, strong pharmaceutical and biotechnology industries, stringent regulatory requirements, and extensive adoption of analytical testing. The National Institute of Standards and Technology (NIST) provides more than 1,200 Standard Reference Materials (SRMs) covering a broad range of applications. These materials support instrument calibration, measurement accuracy, quality assurance, and analytical method development, strengthening the measurement traceability infrastructure in the U.S.
The U.S. Environmental Protection Agency (EPA) has developed Method 1633A for the analysis of 40 PFAS compounds in wastewater, surface water, groundwater, soil, biosolids, sediment, landfill leachate, and fish tissue using isotope-dilution LC-MS/MS. The method has undergone multi-laboratory validation and is proposed for incorporation into 40 CFR Part 136. EPA states that Method 1633A is not nationally required for Clean Water Act compliance monitoring until it is promulgated through rulemaking, although it can already be used in individual permits. The expansion of standardized environmental testing methods is expected to support demand for PFAS analytical standards, isotopically labeled standards, and other reference materials, as laboratories increasingly adopt validated methods for environmental monitoring and regulatory testing.
Asia-Pacific will have the highest CAGR, of approximately 8.0%, supported by the expansion of pharmaceutical, biotechnology, food safety, environmental testing, and research activities across the region. As manufacturers increasingly target international markets, the need for standardized analytical testing, quality control, method validation, and reference materials is increasing. The growing adoption of internationally aligned quality and regulatory practices across pharmaceutical manufacturing is further supporting demand for analytical standards. The Pharmaceutical Inspection Co-operation Scheme (PIC/S) provides a framework for harmonizing GMP inspection practices among participating regulatory authorities, including authorities across several Asia-Pacific markets. This regulatory alignment supports greater consistency in pharmaceutical quality-control practices and analytical testing requirements across the region.
Regional growth is further supported by expanding pharmaceutical and biotechnology manufacturing, increasing environmental and food-safety testing, and the development of laboratory and analytical infrastructure. India's expanding pharmaceutical manufacturing and testing base, China's large pharmaceutical and chemical industries, and South Korea's growing biotechnology and advanced-therapy sector are expected to contribute to regional demand for analytical standards during the forecast period.
China is the largest market within Asia-Pacific, supported by the scale of its pharmaceutical and chemical manufacturing industries and continued investment in research and innovation. The expansion of pharmaceutical production and R&D activities is increasing requirements for analytical testing across drug substance characterization, impurity profiling, quality control, and batch-release testing. According to the Ministry of Industry and Information Technology (MIIT) of the People's Republic of China, pharmaceutical industry main business revenues grew at an average annual rate of 9.3% during the 14th Five-Year Plan period, while combined sector profits increased by 11.3% annually and average annual research and development investment growth exceeded 20%.
This expansion of pharmaceutical manufacturing and R&D activity is expected to support demand for analytical testing, analytical standards, and reference materials. Continued adoption of internationally aligned GMP practices, along with increasing environmental monitoring and regulatory enforcement related to soil, groundwater, and other contaminants, is expected to support demand for analytical standards in China. The development of domestic reference-material production capabilities may further improve the availability of analytical standards and reduce reliance on imported materials over the forecast period.
The regions and countries analyzed in this report are:
The market is fragmented because it comprises a large number of global, regional, and specialized suppliers offering analytical standards across diverse applications, analytes, techniques, and industries. While major companies have extensive portfolios and established distribution networks, no single player dominates the market across all product categories and geographic regions. Suppliers compete through product purity, certification, traceability, regulatory compliance, custom synthesis capabilities, and application-specific standards. The market also includes specialized manufacturers that focus on niche areas such as pharmaceutical impurities, environmental contaminants, food testing, forensic analysis, and biotechnology. Increasing demand for customized and matrix-specific reference materials further supports the presence of smaller specialized suppliers. In addition, differences in regulatory requirements across countries create opportunities for regional companies to serve local laboratories and industries.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages